Sign in

    Sheldon L. Koenig

    President and CEO at Esperion Therapeutics Inc
    Board
    Since May 2021
    Age
    58 years
    Education
    Holds a Master of Business Administration from Monmouth University and a Bachelor of Applied Science from Drexel University.
    Tenure
    Joined Esperion as Chief Operating Officer in December 2020 and was promoted to President and Chief Executive Officer in May 2021.

    Also at Esperion Therapeutics Inc

    BH
    Benjamin Halladay
    Chief Financial Officer
    BL
    Benjamin Looker
    General Counsel
    EW
    Eric Warren
    Chief Commercial Officer

    About

    Sheldon L. Koenig has built an extensive career in the pharmaceutical industry with over 25 years of experience, including leadership roles at Merck & Co., Sanofi, and Portola Pharmaceuticals.

    At Esperion Therapeutics, he has been instrumental in steering strategic initiatives focused on revenue growth, operating profitability, and portfolio expansion. His efforts have led to the development of innovative therapies and strategic product combinations aimed at addressing preventative cardiovascular care.

    His strong academic foundation, underscored by advanced degrees, has enabled him to navigate complex global markets and drive significant advancements in the industry. This blend of strategic vision and operational expertise continues to shape his impactful contributions to the success of Esperion Therapeutics.

    $ESPR Performance Under Sheldon L. Koenig

    Past Roles

    OrganizationRoleDate RangeDetails
    Esperion Therapeutics (ESPR) Chief Operating Officer December 2020 - May 2021 Transitioned to President & CEO in May 2021
    Portola Pharmaceuticals, Inc. Executive Vice President and Chief Commercial Officer January 2019 - August 2020 Served until acquisition by Alexion
    Sanofi S.A. Senior Vice President and Head of the Cardiovascular Franchise January 2016 - July 2018 Led U.S. business operations and international product launches
    Merck & Co., Inc. Vice President and Global Brand Leader for the Cardiovascular Division Over 25 years Held progressively increasing roles and led marketing for the launch of ezetimibe

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$725,000 Annual, 2023Fixed annual base salary.
    All Other Compensation$16,033 Annual, 2023Includes 401(k) matching contributions of $15,000 and personal use of company vehicle of $1,033.

    Performance Compensation

    Data from  FY 2023

    Non-equity Incentive Plan Compensation

    Metric/ComponentWeight/TargetAchievement/ResultAdditional Details
    Execute CVOT presentation, data release, and submissions40%100% achievedPart of Base Corporate Goals.
    Achieve US net sales target25%100% achievedBase corporate goal.
    Prepare for full-scale commercial launch10%100% achievedBase corporate goal.
    Optimize Market Access Environment10%100% achievedBase corporate goal.
    Manage cash used in operations to $215MM10%100% achievedBase corporate goal.
    Continue to progress pipeline value5%100% achievedBase corporate goal.
    Total Base Goals100%Summation of base criteria.
    Simultaneous publication and presentation of topline data from CVOT by March 3110%AchievedStretch Goal.
    Submit filings to EMA/FDA for cardiovascular risk reduction before July 11% per month early; achieved 2%AchievedStretch Goal conditions.
    Exceed US net sales target3%AchievedStretch Goal.
    Total Stretch Goals15%Summation of stretch criteria.
    • Overall Achievement: 115% of target.
    • Target Award Opportunity: 65% of base salary (i.e., 65% of $725,000 = $471,250).
    • Actual Bonus Payment: $541,938 (calculated as 115% of target bonus).
    • Evaluation Period: Performance evaluated during 2023 with final payout in December 2023.
    • Vesting Schedule & Grant Date: Not applicable as the compensation was a cash bonus without equity vesting.